Literature DB >> 26538285

Linking Cancer Metabolism to DNA Repair and Accelerated Senescence.

Elena V Efimova1, Satoe Takahashi1, Noumaan A Shamsi2, Ding Wu1, Edwardine Labay3, Olesya A Ulanovskaya2, Ralph R Weichselbaum3, Sergey A Kozmin2, Stephen J Kron4.   

Abstract

UNLABELLED: Conventional wisdom ascribes metabolic reprogramming in cancer to meeting increased demands for intermediates to support rapid proliferation. Prior models have proposed benefits toward cell survival, immortality, and stress resistance, although the recent discovery of oncometabolites has shifted attention to chromatin targets affecting gene expression. To explore further effects of cancer metabolism and epigenetic deregulation, DNA repair kinetics were examined in cells treated with metabolic intermediates, oncometabolites, and/or metabolic inhibitors by tracking resolution of double-strand breaks (DSB) in irradiated MCF7 breast cancer cells. Disrupting cancer metabolism revealed roles for both glycolysis and glutaminolysis in promoting DSB repair and preventing accelerated senescence after irradiation. Targeting pathways common to glycolysis and glutaminolysis uncovered opposing effects of the hexosamine biosynthetic pathway (HBP) and tricarboxylic acid (TCA) cycle. Treating cells with the HBP metabolite N-acetylglucosamine (GlcNAc) or augmenting protein O-GlcNAcylation with small molecules or RNAi targeting O-GlcNAcase each enhanced DSB repair, while targeting O-GlcNAc transferase reversed GlcNAc's effects. Opposing the HBP, TCA metabolites including α-ketoglutarate blocked DSB resolution. Strikingly, DNA repair could be restored by the oncometabolite 2-hydroxyglutarate (2-HG). Targeting downstream effectors of histone methylation and demethylation implicated the PRC1/2 polycomb complexes as the ultimate targets for metabolic regulation, reflecting known roles for Polycomb group proteins in nonhomologous end-joining DSB repair. Our findings that epigenetic effects of cancer metabolic reprogramming may promote DNA repair provide a molecular mechanism by which deregulation of metabolism may not only support cell growth but also maintain cell immortality, drive therapeutic resistance, and promote genomic instability. IMPLICATIONS: By defining a pathway from deregulated metabolism to enhanced DNA damage response in cancer, these data provide a rationale for targeting downstream epigenetic effects of metabolic reprogramming to block cancer cell immortality and overcome resistance to genotoxic stress. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26538285      PMCID: PMC4755886          DOI: 10.1158/1541-7786.MCR-15-0263

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  66 in total

1.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

2.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

Review 3.  The chromatin response to DNA breaks: leaving a mark on genome integrity.

Authors:  Godelieve Smeenk; Haico van Attikum
Journal:  Annu Rev Biochem       Date:  2013-02-14       Impact factor: 23.643

Review 4.  Small molecule probes of cellular pathways and networks.

Authors:  Adam B Castoreno; Ulrike S Eggert
Journal:  ACS Chem Biol       Date:  2010-11-18       Impact factor: 5.100

Review 5.  Epigenetic modifications in double-strand break DNA damage signaling and repair.

Authors:  Dorine Rossetto; Andrew W Truman; Stephen J Kron; Jacques Côté
Journal:  Clin Cancer Res       Date:  2010-09-07       Impact factor: 12.531

Review 6.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

Review 7.  Histone modifications and DNA double-strand break repair after exposure to ionizing radiations.

Authors:  Clayton R Hunt; Deepti Ramnarain; Nobuo Horikoshi; Puneeth Iyengar; Raj K Pandita; Jerry W Shay; Tej K Pandita
Journal:  Radiat Res       Date:  2013-02-01       Impact factor: 2.841

8.  O-GlcNAcylation regulates EZH2 protein stability and function.

Authors:  Chi-Shuen Chu; Pei-Wen Lo; Yi-Hsien Yeh; Pang-Hung Hsu; Shih-Huan Peng; Yu-Ching Teng; Ming-Lun Kang; Chi-Huey Wong; Li-Jung Juan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

9.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

10.  53BP1 is a reader of the DNA-damage-induced H2A Lys 15 ubiquitin mark.

Authors:  Amélie Fradet-Turcotte; Marella D Canny; Cristina Escribano-Díaz; Alexandre Orthwein; Charles C Y Leung; Hao Huang; Marie-Claude Landry; Julianne Kitevski-LeBlanc; Sylvie M Noordermeer; Frank Sicheri; Daniel Durocher
Journal:  Nature       Date:  2013-06-12       Impact factor: 49.962

View more
  24 in total

1.  O-GlcNAcylation Enhances Double-Strand Break Repair, Promotes Cancer Cell Proliferation, and Prevents Therapy-Induced Senescence in Irradiated Tumors.

Authors:  Elena V Efimova; Oliver K Appelbe; Natalia Ricco; Steve S-Y Lee; Yue Liu; Donald J Wolfgeher; Tamica N Collins; Amy C Flor; Aishwarya Ramamurthy; Sara Warrington; Vytautas P Bindokas; Stephen J Kron
Journal:  Mol Cancer Res       Date:  2019-03-18       Impact factor: 5.852

Review 2.  O-GlcNAc in cancer: An Oncometabolism-fueled vicious cycle.

Authors:  John A Hanover; Weiping Chen; Michelle R Bond
Journal:  J Bioenerg Biomembr       Date:  2018-03-29       Impact factor: 2.945

Review 3.  Targeting 2-oxoglutarate dehydrogenase for cancer treatment.

Authors:  Ling-Chu Chang; Shih-Kai Chiang; Shuen-Ei Chen; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

Review 4.  Rho GTPases in cancer radiotherapy and metastasis.

Authors:  Rui-Jie Zeng; Chun-Wen Zheng; Wan-Xian Chen; Li-Yan Xu; En-Min Li
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

Review 5.  An Emerging Regulatory Role for the Tumor Microenvironment in the DNA Damage Response to Double-Strand Breaks.

Authors:  Tshering D Lama-Sherpa; Lalita A Shevde
Journal:  Mol Cancer Res       Date:  2019-11-01       Impact factor: 5.852

6.  Prognostic value of DNA repair based stratification of hepatocellular carcinoma.

Authors:  Zhuo Lin; Shi-Hao Xu; Hai-Qing Wang; Yi-Jing Cai; Li Ying; Mei Song; Yu-Qun Wang; Shan-Jie Du; Ke-Qing Shi; Meng-Tao Zhou
Journal:  Sci Rep       Date:  2016-05-13       Impact factor: 4.379

7.  O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance.

Authors:  Yubo Liu; Yu Cao; Xiaoqing Pan; Meiyun Shi; Qiong Wu; Tianmiao Huang; Hui Jiang; Wenli Li; Jianing Zhang
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

8.  O-GlcNAcylation Affects the Pathway Choice of DNA Double-Strand Break Repair.

Authors:  Sera Averbek; Burkhard Jakob; Marco Durante; Nicole B Averbeck
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

9.  AMP-activated protein kinase is involved in the activation of the Fanconi anemia/BRCA pathway in response to DNA interstrand crosslinks.

Authors:  Min Jeong Chun; Sunshin Kim; Soo Kyung Hwang; Bong Sub Kim; Hyoun Geun Kim; Hae In Choi; Jong Heon Kim; Sung Ho Goh; Chang-Hun Lee
Journal:  Oncotarget       Date:  2016-08-16

Review 10.  Small-molecule drug repurposing to target DNA damage repair and response pathways.

Authors:  Jacqueline A Brinkman; Yue Liu; Stephen J Kron
Journal:  Semin Cancer Biol       Date:  2020-02-27       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.